<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03253263</url>
  </required_header>
  <id_info>
    <org_study_id>SHP607-202</org_study_id>
    <secondary_id>2018-001393-16</secondary_id>
    <nct_id>NCT03253263</nct_id>
  </id_info>
  <brief_title>A Clinical Efficacy and Safety Study of SHP607 in Preventing Chronic Lung Disease in Extremely Premature Infants</brief_title>
  <official_title>A Phase 2b, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age Compared to Standard Neonatal Care in Extremely Premature Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if an investigational drug can reduce the burden of
      chronic lung disease in extremely premature babies through 12 months corrected age (CA), as
      compared to extremely premature babies receiving standard neonatal care alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Final Weaning off Respiratory Technology Support (RTS) From Day 1 Through 12 Months Corrected age (CA)</measure>
    <time_frame>Baseline through 12 months Corrected Age (CA)</time_frame>
    <description>RTS is defined as any one of the following: (1) supplemental oxygen less than (&lt;) 2 Liter per minute (L/min) without positive pressure (including nasal cannula), (2) positive pressure support (including continuous positive airway pressure [CPAP], nasal cannula oxygen greater than (&gt;) 2 L/min), (3) positive pressure ventilation (high frequency oscillation ventilation and technologies with positive pressure tidal volume breaths, such as mechanical ventilation, nasal intermittent positive pressure ventilation [NIPPV]). Time to final weaning off RTS as compared to a standard neonatal care group will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Bronchopulmonary Dysplasia (BPD) or Death through Postmenstrual age (PMA) 36 Weeks</measure>
    <time_frame>Baseline through 36 weeks postmenstrual age (PMA)</time_frame>
    <description>BPD will be assessed by modified NICHD severity grading and standardized by oxygen challenge testing for all participants. Incidence of BPD (yes/no) (as diagnosed by modified NICHD severity grading at PMA 36 weeks or discharge home, and confirmed by oxygen challenge testing) or death through PMA 36 weeks will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Days on Respiratory Technology Support (RTS) From Birth Through 12 Months Corrected age (CA)</measure>
    <time_frame>Birth through 12 months CA</time_frame>
    <description>RTS is defined as any one of the following: (1) any fraction of inspired oxygen (FiO2) greter than (&gt;) 21 percent (%), (2) noninvasive respiratory support delivered via a nasal interface (e.g., continuous positive airway pressure [CPAP], bilevel positive airway pressure [BiPAP], high flow therapy, nasal intermittent positive pressure ventilation [NIPPV], nasal cannula), (3) invasive respiratory support (mechanical ventilation) via an endotracheal tube or tracheostomy. Total number of days on RTS from birth through 12 months CA will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Re-hospitalizations</measure>
    <time_frame>From neonatal intensive care unit (NICU) discharge through 12 months CA</time_frame>
    <description>Duration of re-hospitalizations due to respiratory diagnoses will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Emergency Room Visits</measure>
    <time_frame>From NICU discharge through 12 months CA</time_frame>
    <description>Number of emergency room visits associated with a respiratory diagnosis will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Respiratory Medication use</measure>
    <time_frame>From NICU discharge through 12 months CA</time_frame>
    <description>Number of days of respiratory medication use (for example, bronchodilators, steroids, leukotriene inhibitors, diuretics) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Signs and Symptoms of Respiratory Disease as Assessed by a 28-day Caregiver-administered Diary Ending at 12 Months Corrected age (CA)</measure>
    <time_frame>11 months CA through 12 months CA</time_frame>
    <description>Incidence of signs and symptoms of respiratory disease (yes/no) at 12 months CA as assessed by a 28-day caregiver-administered diary recording episodes of wheezing, coughing, and respiratory medication will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Chronic Respiratory Morbidity (CRM1) Through 12 Months Corrected age (CA)</measure>
    <time_frame>From NICU discharge through 12 months CA</time_frame>
    <description>A participant will be defined as having CRM1 if he or she experienced/required at least 1 of the 3 following clinical/treatment events, as reported by parents/caregivers and captured by the pulmonary morbidity assessment on at least two 3-month quarters over a 12-month time period: 1. Emergency room visit or hospitalization associated with a respiratory diagnosis, 2. Home RTS, 3. Daily use of respiratory medications (e.g., bronchodilators, steroids, leukotriene inhibitors, diuretics) as reported by caregivers on the pulmonary morbidity assessment. Incidence of CRM1 through 12 months CA will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Chronic Respiratory Morbidity Including Symptoms of Respiratory Disease (CRM2) Through 12 Months Corrected age (CA)</measure>
    <time_frame>From NICU discharge through 12 months CA</time_frame>
    <description>A participant will be defined as having CRM2 if he or she experienced/required at least 1 of the 4 following clinical/treatment events, as reported by parents/caregivers and captured by the pulmonary morbidity assessment on at least two 3-month quarters over a 12-month time period: 1. Emergency room visit or hospitalization associated with a respiratory diagnosis, 2. Home RTS, 3. Daily use of respiratory medications (e.g., bronchodilators, steroids, leukotriene inhibitors, diuretics) as reported by caregivers on the pulmonary morbidity assessment, 4. Symptoms of respiratory disease as defined by presence of cough without cold, or wheeze at least once per week. Incidence of CRM2 through 12 months CA will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Chronic Respiratory Morbidity (CRM3) Through 12 Months Corrected age (CA), as Determined by the Chronic Lung Disease (CLD) of Infancy Severity Score</measure>
    <time_frame>From NICU discharge through 12 months CA</time_frame>
    <description>Severity of chronic respiratory morbidity (CRM3) through 12 months CA will be reported, as determined by the CLD of infancy severity score that will include components such as respiratory hospitalizations, RTS use, and use of respiratory medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Intraventricular Haemorrhage (IVH) Through Postmenstrual age (PMA) 40 weeks, as Assessed by Cranial Ultrasound</measure>
    <time_frame>Baseline through 40 Weeks PMA</time_frame>
    <description>Incidence of IVH through PMA 40 weeks, as assessed by cranial ultrasound, will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor Function at 12 Months Corrected age (CA), as Measured by Alberta Infant Motor Scales (AIMS)</measure>
    <time_frame>At 12 months CA</time_frame>
    <description>The AIMS is a measure of early motor maturation used for assessment of infants at risk for motor delay, focusing on attainment of motor milestones and development of postural control. It consists of 58 items, including assessments in 4 postural positions: prone (21 items), supine (9 items), sitting (12 items) and standing (16 items). Each item is scored as 'observed' or 'not observed'. The scorer identifies the least and most mature item observed. Motor function at 12 months CA, as measured by AIMS will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status as Assessed by PREMature Infant Index (PREMII) at Postmenstrual Age (PMA) 36 Weeks</measure>
    <time_frame>At 36 weeks PMA</time_frame>
    <description>PREMII is a Clinician-Reported Outcome (ClinRO) assessment used to capture overall functional maturation of extremely preterm neonates. Functional Status is defined as what the infant can do with respect to 8 key functional areas (feeding, weight gain, thermoregulation, respiratory support, apnea, bradycardia, desaturation events, and oxygen administration), as a reflection of the infant's overall health and development.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Retinopathy of Prematurity (ROP)</measure>
    <time_frame>31 weeks through 40 weeks PMA</time_frame>
    <description>The ROP examination will consist of a dilated fundus examination. Typically ROP is classified according to the International Classification and is subdivided into Stage 1 (demarcation line), Stage 2 (ridge), Stage 3 (ridge with extraretinal fibrovascular proliferations), Stage 4 (subtotal retinal detachment), and Stage 5 (total retinal detachment). Incidence of ROP will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Mortality</measure>
    <time_frame>From birth through 12 months CA</time_frame>
    <description>Mortality from birth through 12 months CA will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exposure-response of Insulin-like Growth Factor-1 (IGF-1)</measure>
    <time_frame>Up to 12 months CA</time_frame>
    <description>Exposure response of IGF-1 will be evaluated using (Pharmacokinetic/Pharmacodynamic [PK/PD]) relationship of IGF-1 between respiratory and neurologic endpoints.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">477</enrollment>
  <condition>Retinopathy of Prematurity (ROP)</condition>
  <condition>Intraventricular Hemorrhage</condition>
  <condition>Bronchopulmonary Dysplasia</condition>
  <condition>Chronic Lung Disease of Prematurity</condition>
  <arm_group>
    <arm_group_label>SHP607 250 mcg/kg/24 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive continuous intravenous (IV) infusion of SHP607 250 micrograms per kilogram per 24 hours (mcg/kg/24 hours) from birth up to postmenstrual age (PMA) 29 weeks +6 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHP607 400 mcg/kg/24 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive continuous IV infusion of SHP607 400 mcg/kg/24 hours through from birth up to PMA 29 weeks +6 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Neonatal Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard neonatal care alone will be provided.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHP607</intervention_name>
    <description>Participants will receive intravenous infusion of SHP607 at doses of 250 mcg/kg/24 hours and 400 mcg/kg/24 hours from birth up to PMA 29 weeks + 6 days.</description>
    <arm_group_label>SHP607 250 mcg/kg/24 hours</arm_group_label>
    <arm_group_label>SHP607 400 mcg/kg/24 hours</arm_group_label>
    <other_name>Mecasermin Rinfabate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consents and/or assents must be signed and dated by the participant's
             parent(s) prior to any study related procedures. The informed consent and any assents
             for underage parents must be approved by the institutional review board
             (IRB)/independent ethics committee (IEC).

          2. Written informed consents and/or assents must be signed and dated by the participant's
             birth mother prior to providing study-related information related to birth mother
             medical history, pregnancy and the birth of the participant. The informed consent and
             any assents for underage birth mothers must be approved by the IRB/IEC.

          3. Initially, participants must be between gestational age (GA) of 26 weeks +0 days and
             27 weeks +6 days, inclusive. After approximately 75 participants (approximately 25
             participants in each treatment group) have completed the postmenstrual age (PMA) 40
             weeks visit, an independent data monitoring committee (DMC) will assess safety data
             and may authorize enrollment of participants of GA between 23 weeks +0 days and 27
             weeks +6 days, inclusive.

        Exclusion Criteria:

          1. Detectable major (or severe) congenital malformation identified before randomization.

          2. Known or suspected chromosomal abnormality, genetic disorder, or syndrome, identified
             before randomization, according to the investigator's opinion.

          3. Hypoglycemia at Baseline (blood glucose less than (&lt;) 45 milligrams per deciliter
             [mg/dL] or 2.5 milli moles per liter [mmol/L]) which persists in spite of glucose
             supplementation, to exclude severe congenital abnormalities of glucose metabolism.

          4. Clinically significant neurological disease identified before randomization according
             to cranial ultrasound (hemorrhages confined to the germinal matrix are allowed) and
             investigator's opinion.

          5. Any other condition or therapy that, in the investigator's opinion, may pose a risk to
             the participant or interfere with the participant's potential compliance with this
             protocol or interfere with interpretation of results.

          6. Current or planned participation in a clinical study of another investigational study
             drug, device, or procedure (participation in observational studies is permitted on a
             case-by-case basis).

          7. The participant or participant's parent(s) is/are unable to comply with the protocol
             or is unlikely to be available for long-term follow-up as determined by the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Day</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of South Alabama Children's and Women's Hospital</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>251-415-1055; 251-451-1270</phone>
    </contact>
    <investigator>
      <last_name>Fabien Eyal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202-3500</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>501-364-2596</phone>
    </contact>
    <investigator>
      <last_name>Sherry Courtney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>501-526-7984</phone>
    </contact>
    <investigator>
      <last_name>Sherry Courtney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>310-794-8864; 310-825-9330</phone>
    </contact>
    <investigator>
      <last_name>Meena Garg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>813-844-3437</phone>
    </contact>
    <investigator>
      <last_name>Steven Ford</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>312-355-4038</phone>
    </contact>
    <investigator>
      <last_name>De-Ann Pillers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital of South Bend</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>574-647-3048</phone>
    </contact>
    <investigator>
      <last_name>Basharat Buchh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Baptist Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>504-894-2619; 504-842-4832</phone>
    </contact>
    <investigator>
      <last_name>Amanda England, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Wayne State University Hutzel Women's Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>601-815-3070</phone>
    </contact>
    <investigator>
      <last_name>Abhay Bhatt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jersey Shore University Medical Center</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(732) 776-4693, (732) 776-4287</phone>
    </contact>
    <investigator>
      <last_name>Eduardo Bautista, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bristol Myers Squibb Children's Hospital at Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>732-235-5691</phone>
    </contact>
    <investigator>
      <last_name>Surasak Puvabanditsin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>405-271-5215</phone>
      <phone_ext>42169</phone_ext>
    </contact>
    <investigator>
      <last_name>Faizah Bhatti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina Children Hospital</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>843-792-8829</phone>
    </contact>
    <investigator>
      <last_name>Carol Wagner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University - Children's Hospital of Richmond at VCU</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>804-828-9602; 804-628-3921</phone>
    </contact>
    <investigator>
      <last_name>Henry Rozycki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>304-293-1202</phone>
      <email>mpolak@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Polak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Sinai Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>414-828-3708</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Garland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oulun Yliopistollinen Sairaala</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+35883155845</phone>
    </contact>
    <investigator>
      <last_name>Mikko Hallman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(972) 483-5955</phone>
      <phone_ext>9</phone_ext>
    </contact>
    <investigator>
      <last_name>David Bader</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A Gemelli</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390635510232</phone>
    </contact>
    <investigator>
      <last_name>Giovanni Vento</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi SOD Neonatologia e Terapia Intensiva Neonatale</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390557947792</phone>
    </contact>
    <investigator>
      <last_name>Carlo Dani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini-Istituto Pediatrico di Ricovero e</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+393385095030</phone>
    </contact>
    <investigator>
      <last_name>Luca Ramenghi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Di Treviso Ca' Foncello</name>
      <address>
        <city>Treviso</city>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3904223222666</phone>
    </contact>
    <investigator>
      <last_name>Paola Lago</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kagoshima City Hospital</name>
      <address>
        <city>Kagoshima-shi</city>
        <state>Kagosima</state>
        <zip>890-8760</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+81992307000</phone>
    </contact>
    <investigator>
      <last_name>Satoshi Ibara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saitama Medical Center</name>
      <address>
        <city>Kawagoe-shi</city>
        <state>Saitama</state>
        <zip>350-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+81492283727</phone>
    </contact>
    <investigator>
      <last_name>Fumihiko Namba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>82-2-2072-1696;82-2-2072-0647</phone>
    </contact>
    <investigator>
      <last_name>Han Suk Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>82-2-2228-0400;82-10-8740-1611</phone>
    </contact>
    <investigator>
      <last_name>Min Soo Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Garcia de Orta</name>
      <address>
        <city>Almada</city>
        <zip>2801-951</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+351914021367</phone>
    </contact>
    <investigator>
      <last_name>Anselmo Costa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maternidade Alfredo da Costa</name>
      <address>
        <city>Lisboa</city>
        <zip>1069-089</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+351213184000</phone>
    </contact>
    <investigator>
      <last_name>Teresa Tomé</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+351210405814</phone>
    </contact>
    <investigator>
      <last_name>Andre Graca</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Materno Infantil do Norte - Centro Hospital Universitario do Porto, E.P.E.</name>
      <address>
        <city>Porto</city>
        <zip>4050-651</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+351222077500</phone>
    </contact>
    <investigator>
      <last_name>Eliza Proença Fernandes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Unversitario de Santiago</name>
      <address>
        <city>Santiago Do Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34981950162</phone>
    </contact>
    <investigator>
      <last_name>Maria Luz Couce Pico</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34965913432</phone>
    </contact>
    <investigator>
      <last_name>Caridad Tapia Collados</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Unversitari de Tarragona Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <zip>43007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34977295800</phone>
    </contact>
    <investigator>
      <last_name>Albert Batista</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skanes Universitetssjukhus</name>
      <address>
        <city>Lund</city>
        <zip>SE-22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+4646171000</phone>
    </contact>
    <investigator>
      <last_name>David Ley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+46725968444</phone>
    </contact>
    <investigator>
      <last_name>Alexander Rakow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <state>Norfolk</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+4401603646106</phone>
    </contact>
    <investigator>
      <last_name>Paul Clarke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ashford and St. Peter's Hospitals NHS Trust - St. Peter's Hospital</name>
      <address>
        <city>Chertsey</city>
        <state>Surrey</state>
        <zip>KT16 0PZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+4401932722015</phone>
    </contact>
    <investigator>
      <last_name>Peter Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 15, 2017</study_first_submitted>
  <study_first_submitted_qc>August 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2017</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mecasermin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>De-identified individual participant data from this particular study will not be shared in order to minimize the risk that individual patients could be re-identified, given that there are limited numbers of study participants at each study site per year.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

